China FDA Lays Out eCTDs, Bioequivalence, Patent Linkage As Priorities
Surprise announcement by China FDA to roll out an electronic common technical document system by year-end is causing jitters in the pharma industry, but other moves to raise product quality and strengthen patent linkage seem more positive for manufacturers.
You may also be interested in...
The China FDA releases a raft of new regulatory proposals outlining fundamental changes in areas including patent linkage and data exclusivity, which look set to profoundly impact decision makers looking at bringing new drugs and devices to the world’s second-largest pharma market.
A major European business group in China is encouraged by recent signals of further policy reforms, but says in a new report it would like to see further progress on drug and device tenders, the lifting of indirect competition restrictions, and full implementation of the central push for a level playing field for foreign firms.
Off-patent original drugs in China are set to face unprecedented competition as the country drives up policy support for high-quality, bioequivalent domestic generics, and outlines other sweeping moves covering pricing and compulsory licenses.